Clinical Edge Journal Scan

Post-CRT sarcopenia predicts worse outcomes in locally advanced rectal cancer


 

Key clinical point: Pre-operative sarcopenia predicted shorter disease-free survival (DFS), overall survival (OS), and recurrence of the liver in patients with lower advanced rectal cancer receiving preoperative adjuvant chemoradiotherapy (CRT).

Major finding : Post-CRT sarcopenia was an independent prognostic factor for shorter DFS (hazard ratio [HR], 2.01; P = .049), OS (HR, 1.76; P = .036), and recurrence in the liver (HR, 3.01; P = .025).

Study details: Findings are from a retrospective analysis of 234 patients with cT3-T4 anyN M0 lower rectal cancer who underwent CRT (5-fluorouracil-based oral chemotherapy and long course radiation) followed by radical surgery.

Disclosures: This study was supported by Japan Society for the Promotion of Science and Japan Agency for Medical Research and Development. The authors declared no conflict of interests.

Source: Abe S et al. Int J Clin Oncol. 2021 Nov 6. doi: 10.1007/s10147-021-02062-z .

Recommended Reading

Balloon-enhanced colonoscopy finds more adenomas
MDedge Hematology and Oncology
Dogs show potential as medical detectives in breast cancer
MDedge Hematology and Oncology
Severe COVID two times higher for cancer patients
MDedge Hematology and Oncology
A single flexible sigmoidoscopy shows strong protective effect for CRC incidence and mortality
MDedge Hematology and Oncology
Simultaneous colectomy and HAIP placement safe in liver metastases of colon carcinoma
MDedge Hematology and Oncology
Young age tied with higher risk for relapse in high-risk stage III CRC
MDedge Hematology and Oncology
Higher intake of preserved vegetables and colorectal polyps: What is the link?
MDedge Hematology and Oncology
Preoperative SCRT with subsequent CAPOX and camrelizumab shows promise in locally advanced rectal cancer
MDedge Hematology and Oncology
Complications and outcomes of different management pathways of CRC and synchronous liver metastases
MDedge Hematology and Oncology
Immune checkpoint inhibitors and regorafenib combo shows promising efficacy in MSS CRC
MDedge Hematology and Oncology